Empowering MSMEs with News & Insights

60 Pharma MSME applications registered for PTUAS scheme till date

Updated: Dec 14, 2022 08:42:44am
image

60 Pharma MSME applications registered for PTUAS scheme till date

New Delhi, Dec 14 (KNN) About 60 applications from MSMEs have been registered until now for the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), informed Minister of State for Chemicals and Fertilizers, Bhagwanth Khuba in a written reply in Rajya Sabha on Tuesday.

PTUAS is a credit linked scheme and under this applications are invited from eligible Pharma MSME units since August 1, 2022.

FOLLOW US on GOOGLE NEWS

For registration of application, online portal has been developed by SIDBI, the Project Management Consultant (PMC) of the scheme and details are available at https://spi.udyamimitra.in.

However, the PTUAS has been incorporated as a sub-scheme under the Scheme - Strengthening of Pharmaceutical Industry (SPI), which was launched in July 2022.

The Strengthening of Pharmaceutical Industry (SPI), with the financial outlay of Rs 500 crore and with a tenure from FY 2021-2022 to FY 2025-26, has following three components, to provide infrastructure support for pharma MSMEs in clusters and to address the issues of technology upgradation of individual pharma MSMEs.

The sub-scheme PTUAS is aimed to facilitate MSMEs of proven track record to meet national and international regulatory standards (WHO-GMP or Schedule-M), interest subvention or capital subsidy on their capital loans will be provided, which will further facilitate the growth in volumes as well as in quality and it is ensivaged to support about 400 Pharma MSME units under this sub-scheme during the scheme tenure.

Further, one national and 10 State level outreach events were conducted, involving the State Governments and Pharma Industry Associations for maximum outreach and awareness for larger participation by Pharma MSME industries to avail the scheme benefits. (KNN Bureau)

COMMENTS

    Be first to give your comments.

LEAVE A REPLY

Required fields are marked *